Advisory Services Network’s Oramed Pharmaceuticals ORMP Stock Holding History

Advisory Services Network’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500	Closed	-$1.09K	–	2948
2023 Q1	$1.09K	Hold	500	–	–	﹤0.01%	3595
2022 Q4	$6.01K	Buy	+500	New	+$3.89K	﹤0.01%	3056
2021 Q3	–	Sell	-500	Closed	-$7K	–	2653
2021 Q2	$7K	Buy	+500	New	+$5.72K	﹤0.01%	2958
2016 Q3	–	Sell	-1,086	Closed	-$9K	–	2046
2016 Q2	$9K	Buy	+1,086	New	+$9.25K	﹤0.01%	1243
2014 Q1	–	Sell	-285	Closed	-$4K	–	628
2013 Q4	$4K	Buy	+285	New	+$2.2K	﹤0.01%	862

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Advisory Services Network's ORMP Position: Q2 2023 in Review

Advisory Services Network sold out of Oramed Pharmaceuticals (ORMP) in Q2 2023, closing a stake of 500 shares — an estimated $1.09K sold.

Advisory Services Network first reported a position in ORMP in Q4 2013 and held it in 5 quarters. The position peaked at $9K in Q2 2016. 50 funds tracked by Wall St. Rank hold ORMP as of Q2 2023.

Advisory Services Network reported no remaining Oramed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Advisory Services Network sold 500 Oramed Pharmaceuticals shares in Q2 2023, an estimated $1.09K.
Advisory Services Network first reported a position in Oramed Pharmaceuticals in Q4 2013 and held it in 5 quarters.
Advisory Services Network's Oramed Pharmaceuticals position peaked at $9K in Q2 2016.
50 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2023.

Based on Advisory Services Network's 13F filing for Q2 2023, filed 9 Aug 2023.